Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619

British Journal of Pharmacology

Volumn 152, Issue 5, 2007, Pages 691-698

  Hillard, C J ^a   Ho, W S V ^a,c   Thompson, J ^a   Gauthier, K M ^a   Wheelock, C E ^b,d   Huang, H ^b   Hammock, B D ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

2 arachidonoylglycerol; Cannabinoid receptor; CB 1 receptor; DETFP; Endocannabinoid; Fatty acid amide hydrolase; Middle cerebral artery; Monoacylglycerol lipase; U 46619; URB754

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 ARACHIDONOYLGLYCEROL; 3 (DECYLTHIO) 1,1,1, TRIFLUROPROPAN 2 ONE; CANNABINOID 1 RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE INHIBITOR; SEROTONIN; THROMBOXANE; UNCLASSIFIED DRUG; URB 754;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY DILATATION; ARTERY PERFUSION; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; FEEDBACK SYSTEM; LIPOLYSIS; MALE; MICROSCOPY; MIDDLE CEREBRAL ARTERY; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RAT; STROKE; THROMBOSIS; VASOCONSTRICTION; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AMIDOHYDROLASES; ANILINE COMPOUNDS; ANIMALS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; BENZAMIDES; BENZOXAZINES; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; GLYCERIDES; MALE; MIDDLE CEREBRAL ARTERY; MORPHOLINES; NAPHTHALENES; NIMODIPINE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; THROMBOXANES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 35649005473     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707468     Document Type: Article

References (39)

1. Ashton JC, Zheng Y, Liu P, Darlington CL, Smith PF (2004). Immunohistochemical characterisation and localisation of cannabinoid CB1 receptor protein in the rat vestibular nucleus complex and the effects of unilateral vestibular deafferentation. Brain Res 1021: 264-271.
2. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322: 671-677.
3. Chen Y, McCarron RM, Ohara Y, Bembry J, Azzam N, Lenz FA et al. (2000). Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1. Circ Res 87: 323-327.
4. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483: 52-56.
5. Dewey WL (1986). Cannabinoid pharmacology. Pharmacol Rev 38: 151-178.
6. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA et al. (1999a). Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 264: 258-267.
7. Di Marzo V, De Petrocellis L, Bisogno T, Melck D (1999b). Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids 34 (Suppl): S319-S325.
8. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99: 10819-10824.
9. Dinh TP, Kathuria S, Piomelli D (2004). RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66: 1260-1264.
10. Ellis EF, Moore SF, Willoughby KA (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol 269: H1859-H1864.
11. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A et al. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101: 8756-8761.
12. Gauthier-Rein KM, Bizub DM, Lombard JH, Rusch NJ (1997). Hypoxia-induced hyperpolarization is not associated with vasodilation of bovine coronary resistance arteries. Am J Physiol 272: H1462-H1469.
13. 2+ channel current. Am J Physiol 276: H2085-H2093.
14. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S (1999). Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57: 417-423.
15. Hillard CJ (2000a). Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat 61: 3-18.
16. Hillard CJ (2000b). Endocannabinoids and vascular function. J Pharmacol Exp Ther 294: 1-6.
17. Ho WS, Randall MD (2007). Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol. Br J Pharmacol 150: 641-651.
18. Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ (1999). Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem 72: 2379-2387.
19. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al. (2005). Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8: 1139-1141.
20. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al. (2007). Selective inhibition if 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus (Corrigendum). Nat Neurosci 10: 134.
21. Mathew R, Wilson W (1993). Acute changes in cerebral blood flow after smoking marijuana. Life Sci 52: 757-767.
22. Mathew RJ, Wilson WH, Davis R (2003). Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav 75: 309-318.
23. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE (1992a). Middle cerebral artery velocity during upright posture after marijuana smoking. Acta Psychiatr Scand 86: 173-178.
24. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE (1992b). Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab 12: 750-758.
25. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB (2005). A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332: 1028-1033.
26. Pacher P, Batkai S, Kunos G (2005). Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 186: 599-625.
27. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS et al. (2005). The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46: 342-349.
28. Rademacher DJ, Meier SE, Shi L, Ho W-SV, Jarrahian A, HIllard CJ (2007). Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum and medial prefrontal cortex in mice. Neuropharmacol (in press).
29. Rademacher DJ, Patel S, Ho WS, Savoie AM, Rusch NJ, Gauthier KM et al. (2005). U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance. Am J Physiol Heart Circ Physiol 288: H2694-H2701.
30. Roman RJ, Renic M, Dunn KM, Takeuchi K, Hacein-Bey L (2006). Evidence that 20-HETE contributes to the development of acute and delayed cerebral vasospasm. Neurol Res 28: 738-749.
31. Saario SM, Palomaki V, Lehtonen M, Nevalainen T, Jarvinen T, Laitinen JT (2006). URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. Chem Biol 13: 811-814.
32. Saario SM, Savinainen JR, Laitinen JT, Jarvinen T, Niemi R (2004). Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol 67: 1381-1387.
33. 2+ transient in NG108-15 cells. J Biochem (Tokyo) 122: 890-895.
34. Vandevoorde S, Fowler CJ (2005). Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol 145: 885-893.
35. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ (2007). Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150: 186-191.
36. von Holst H, Granstrom E, Hammarstrom S, Samuelsson B, Steiner L (1982). Effect of leucotrienes C4, D4, prostacyclin and thromboxane A2 on isolated human cerebral arteries. Acta Neurochir (Wien) 62: 177-185.
37. Wadkins RM, Hyatt JL, Edwards CC, Tsurkan L, Redinbo MR, Wheelock CE et al. (2007). Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. Mol Pharmacol 71: 713-723.
38. Wagner JA, Jarai Z, Batkai S, Kunos G (2001). Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. Eur J Pharmacol 423: 203-210.
39. Wheelock CE, Severson TF, Hammock BD (2001). Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility. Chem Res Toxicol 14: 1563-1572.